Last $159.30 USD
Change Today +2.43 / 1.55%
Volume 1.1M
JAZZ On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:40 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (JAZZ) Snapshot

Open
$156.39
Previous Close
$156.87
Day High
$161.25
Day Low
$155.14
52 Week High
02/25/14 - $176.60
52 Week Low
08/20/13 - $80.20
Market Cap
9.6B
Average Volume 10 Days
1.3M
EPS TTM
$2.15
Shares Outstanding
60.2M
EX-Date
--
P/E TM
74.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (JAZZ)

jazz pharmaceuticals plc (JAZZ) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (JAZZ) Details

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

830 Employees
Last Reported Date: 08/5/14

jazz pharmaceuticals plc (JAZZ) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $771.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $419.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $547.0K
Executive Vice President and General Counsel
Total Annual Compensation: $536.0K
Consultant
Total Annual Compensation: $472.7K
Compensation as of Fiscal Year 2013.

jazz pharmaceuticals plc (JAZZ) Key Developments

Jazz Pharmaceuticals Public Limited Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reports Intangible Asset Impairment Charges for the Second Quarter Ended June 30, 2014; Provides Earnings Guidance for the Year 2014; Appoints Elmar Schnee to the Board of Directors

Jazz Pharmaceuticals Public Limited Company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of USD 291,230,000 against USD 208,252,000 a year ago. Income from operations was USD 74,291,000 against USD 77,066,000 a year ago. Income before income tax provision was USD 62,936,000 against USD 65,790,000 a year ago. Net income attributable to the company was USD 43,659,000 or USD 0.70 per share diluted against USD 42,185,000 or USD 0.69 per share diluted a year ago. Non-GAAP adjusted net income attributable to the company was USD 127,790,000 or USD 2.05 per share diluted against USD 88,309,000 or USD 1.43 per share diluted a year ago. Non-GAAP adjusted income before income tax provision was USD 158,211,000 against USD 107,937,000 a year ago. The increase in revenues were driven primarily by net product sales of Xyrem (sodium oxybate) oral solution, Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi) and defibrotide, marketed under the name Defitelio (defibrotide) in Europe. For the six months, the company reported total revenues of USD 538,149,000 against USD 404,489,000 a year ago. Income from operations was USD 7,632,000 against USD 145,253,000 a year ago. Loss before income tax provision was USD 13,676,000 against income before income tax provision of USD 126,849,000 a year ago. Net loss attributable to the company was USD 48,991,000 or USD 0.83 per share diluted against net income attributable to the company of USD 85,610,000 or USD 1.39 per share diluted a year ago. Non-GAAP adjusted net income attributable to the company was USD 228,637,000 or USD 3.66 per share diluted against USD 172,734,000 or USD 2.81 per share diluted a year ago. Non-GAAP adjusted income before income tax provision was USD 282,298,000 against USD 211,128,000 a year ago. For the quarter, the company reported intangible asset impairment charges of USD 32,806,000, related to certain products acquired as part of the acquisition of EUSA Pharma Inc. The company provided earnings guidance for the year 2014. For the year, the company expects GAAP net income attributable to the company to be in the range of USD 29 million to USD 57 million, intangible asset amortization and depreciation to be in the range of USD 129 million to USD 134 million, non-GAAP adjusted net income attributable to the company to be in the range of USD 496 million to USD 520 million, GAAP net income attributable to the company per diluted share to be in the range of USD 0.47 to USD 0.90 and non-GAAP net income attributable to the company per diluted share to be in the range of USD 8.00 million to USD 8.25. The company expects revenues to be in the range of USD 1,125 million to USD 1,165 million and adjusted gross margin to be in the range of 91% to 92%. The company announced that Elmar Schnee joined the company's board of directors on August 1, 2014. He previously served as a director of Gentium from May 2012 to April 2014. Mr. Schnee brings to the company's board of directors over 30 years of international commercial and general management experience in the pharmaceutical and healthcare industries, as well as detailed knowledge of the Gentium business. From October 2011 until November 2013, he served as Chairman and Chief Executive Officer at Cardiorentis Ltd. Previously, he served in various positions at Merck KGaA, from 2003 through 2011, including as a Member of the Executive Board and General Partner of Merck KGaA from 2006 until 2011. He currently serves on the board of directors of two privately-held life sciences companies.

Jazz Pharmaceuticals Public Limited Company to Report Q2, 2014 Results on Aug 05, 2014

Jazz Pharmaceuticals Public Limited Company announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 05, 2014

Jazz Pharmaceuticals Public Limited Company, Q2 2014 Earnings Call, Aug 05, 2014

Jazz Pharmaceuticals Public Limited Company, Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $159.21 USD +2.34

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Momenta Pharmaceuticals Inc $11.40 USD -0.21
View Industry Companies
 

Industry Analysis

JAZZ

Industry Average

Valuation JAZZ Industry Range
Price/Earnings 100.0x
Price/Sales 9.3x
Price/Book 7.4x
Price/Cash Flow 50.9x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.